Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

4Q14 US Copaxone sales:

http://finance.yahoo.com/news/teva-reports-fourth-quarter-full-120000228.html

In the United States, sales of Copaxone amounted to $835 million, up 4% compared to the fourth quarter of 2013. At the end of the fourth quarter of 2014, according to December 2014 IMS data, our U.S. market shares for the Copaxone products in terms of new and total prescriptions were 25.9% and 31.5%, respectively. Copaxone 40 mg/mL accounted for over 60% of total Copaxone prescriptions.